Top Markets
#1 Merlin's Seal BTC Merlin's Seal BTC +42.51%
#2 SAFEcoin SAFEcoin +29.03%
#3 Zora Zora +27.23%
#4 Pons Pons +27.21%
#5 0G 0G +25.84%
#6 QuantixAI QuantixAI +24.35%
#7 AI XOVIA AI XOVIA +18.73%
#8 Verus Coin Verus Coin +17.85%
#9 StonkBroker StonkBroker +17.56%
#10 ADO Protocol ADO Protocol +17.06%
Coin of the day
Merlin's Seal BTC Merlin's Seal BTC
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Hansa Biopharma AB (publ) Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ)

HNSA
Peringkat dalam Saham #13465
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing... Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
Harga Saham
$4.88
Kapitalisasi Pasar
$487.02M
Perubahan (1 hari)
-1.84%
Perubahan (1 tahun)
42.78%
Negara
SE
Perdagangan Hansa Biopharma AB (publ) (HNSA)

Kategori

Healthcare
Rasio P/E untuk Hansa Biopharma AB (publ) (HNSA)
Rasio P/E per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Hansa Biopharma AB (publ), rasio P/E saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki rasio P/E sebesar 0.
Riwayat rasio P/E untuk Hansa Biopharma AB (publ) dari 2026 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.